357 related articles for article (PubMed ID: 30686950)
21. Real-world evidence and product development: Opportunities, challenges and risk mitigation.
Naidoo P; Bouharati C; Rambiritch V; Jose N; Karamchand S; Chilton R; Leisegang R
Wien Klin Wochenschr; 2021 Aug; 133(15-16):840-846. PubMed ID: 33837463
[TBL] [Abstract][Full Text] [Related]
22. Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments.
Schneeweiss S; Patorno E
Endocr Rev; 2021 Sep; 42(5):658-690. PubMed ID: 33710268
[TBL] [Abstract][Full Text] [Related]
23. Making Clinical Practice Guidelines Pragmatic: How Big Data and Real World Evidence Can Close the Gap.
Chew SY; Koh MS; Loo CM; Thumboo J; Shantakumar S; Matchar DB
Ann Acad Med Singap; 2018 Dec; 47(12):523-527. PubMed ID: 30636269
[TBL] [Abstract][Full Text] [Related]
24. Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making.
Franklin JM; Glynn RJ; Martin D; Schneeweiss S
Clin Pharmacol Ther; 2019 Apr; 105(4):867-877. PubMed ID: 30636285
[TBL] [Abstract][Full Text] [Related]
25. Digital Health and Big Data Analytics: Implications of Real-World Evidence for Clinicians and Policymakers.
Magalhães T; Dinis-Oliveira RJ; Taveira-Gomes T
Int J Environ Res Public Health; 2022 Jul; 19(14):. PubMed ID: 35886214
[TBL] [Abstract][Full Text] [Related]
26. Using RWE research to extend clinical trials in diabetes: An example with implications for the future.
Seeger JD; Nunes A; Loughlin AM
Diabetes Obes Metab; 2020 Apr; 22 Suppl 3(Suppl 3):35-44. PubMed ID: 32250529
[TBL] [Abstract][Full Text] [Related]
27. How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancer.
Saesen R; Kantidakis G; Marinus A; Lacombe D; Huys I
Front Pharmacol; 2022; 13():969778. PubMed ID: 36091761
[No Abstract] [Full Text] [Related]
28. Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics.
Phillips CM; Parmar A; Guo H; Schwartz D; Isaranuwatchai W; Beca J; Dai W; Arias J; Gavura S; Chan KKW
Cancer; 2020 Apr; 126(8):1717-1726. PubMed ID: 31913522
[TBL] [Abstract][Full Text] [Related]
29. Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.
Clausen M; Mighton C; Kiflen R; Sebastian A; Dai WF; Mercer RE; Beca JM; Isaranuwatchai W; Chan KKW; Bombard Y
CMAJ Open; 2020; 8(4):E772-E778. PubMed ID: 33234584
[TBL] [Abstract][Full Text] [Related]
30. Examining Endpoint Concordance in Clinical Trials and Real-World Clinical Practice to Advance Real-World Evidence Utilization.
Schaumberg D; Larholt K; Apgar E; Pashos CL; Hirsch G
Ther Innov Regul Sci; 2023 May; 57(3):472-475. PubMed ID: 36624361
[TBL] [Abstract][Full Text] [Related]
31. Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?
Malone DC; Brown M; Hurwitz JT; Peters L; Graff JS
Value Health; 2018 Mar; 21(3):326-333. PubMed ID: 29566840
[TBL] [Abstract][Full Text] [Related]
32. Use of real-world evidence for healthcare decision-making in the Middle East: practical considerations and future directions.
Akhras KS; Alsheikh-Ali AA; Kabbani S
Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):245-250. PubMed ID: 30626231
[TBL] [Abstract][Full Text] [Related]
33. Unraveling innovation potential in the real-world setting: eighteen novel agents with twenty-six approved European indications, in the management of leukemias, lymphomas, and multiple myeloma.
Petrakis I; Kontogiorgis C; Nena E; Athanasakis K; Gougoula V; Kotsianidis I; Constantinidis TC
Expert Rev Hematol; 2019 Dec; 12(12):1063-1075. PubMed ID: 31524011
[No Abstract] [Full Text] [Related]
34. Conducting real-world evidence studies in India.
Bhatt A
Perspect Clin Res; 2019; 10(2):51-56. PubMed ID: 31008069
[TBL] [Abstract][Full Text] [Related]
35. Tactical Considerations for Designing Real-World Studies: Fit-for-Purpose Designs That Bridge Research and Practice.
Dreyer NA; Mack CD
Pragmat Obs Res; 2023; 14():101-110. PubMed ID: 37786592
[TBL] [Abstract][Full Text] [Related]
36. Use of Structured Template and Reporting Tool for Real-World Evidence for Critical Appraisal of the Quality of Reporting of Real-World Evidence Studies: A Systematic Review.
Khambholja K; Gehani M
Value Health; 2023 Mar; 26(3):427-434. PubMed ID: 36210293
[TBL] [Abstract][Full Text] [Related]
37. Building trust in real world evidence (RWE): moving transparency in RWE towards the randomized controlled trial standard.
White R
Curr Med Res Opin; 2023 Dec; 39(12):1737-1741. PubMed ID: 37787381
[TBL] [Abstract][Full Text] [Related]
38. Real-World Evidence to Reinforce Clinical Trial Evidence in Health Technology Assessment: A Critical Review of Real-World Evidence Requirements from Seven Countries and Recommendations to Improve Acceptance.
Thokagevistk K; Coppo C; Rey L; Carelli A; Díez V; Vaselenak S; Oliveira L; Patel A; Sicari E; Ramos T; Schach S; Schirghuber E; Simpson A; Choquet R; Le Lay K
J Mark Access Health Policy; 2024 Jun; 12(2):105-117. PubMed ID: 38808313
[TBL] [Abstract][Full Text] [Related]
39. Real-World Evidence to Assess Medication Safety or Effectiveness in Children: Systematic Review.
Lasky T; Carleton B; Horton DB; Kelly LE; Bennett D; Czaja AS; Gifkins D; Osokogu OU; McMahon AW
Drugs Real World Outcomes; 2020 Jun; 7(2):97-107. PubMed ID: 32112359
[TBL] [Abstract][Full Text] [Related]
40. The present and future scope of real-world evidence research in diabetes: What questions can and cannot be answered and what might be possible in the future?
Zaccardi F; Davies MJ; Khunti K
Diabetes Obes Metab; 2020 Apr; 22 Suppl 3():21-34. PubMed ID: 32250528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
